ScholarWorks@Korea University College of Medicine: Jeong, Seogsong

Detailed Information

Jeong, Seogsong (정석송)

College of Medicine (Department of Medical Informatics)

Research Area

Tel 02-3407-4085
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

hepatocellular carcinoma:6||cohort study:6||Hepatocellular carcinoma:5||antibiotics:5||epidemiology:5||Cardiovascular disease:5||Cardiovascular diseases:5||cardiovascular disease:5||SARSCoV2:4||Dementia:4||Fatty liver:4||Cohort study:4||nomogram:4||Epidemiology:4||nonalcoholic fatty liver disease:4||Prognosis:3||risk factor:3||dementia:3||COVID19:3||Antibiotics:3||prognosis:3||COVID19 vaccine:3||Depression:3||Nomogram:3||Nonalcoholic fatty liver disease:3||Public health:3||health screening:3||Mass screening:3||Fatty liver index:2||liver transplantation:2||Biliary malignancy:2||lymph node metastasis:2||Nonalcoholic fatty liver disease:2||Steatotic liver disease:2||Stroke:2||Nonalcoholic fatty liver disease (NAFLD):2||Metabolic dysfunctionassociated steatotic liver disease:2||Liver neoplasms:2||Obesity:2||nonalcoholic steatohepatitis:2||Coronary heart disease:2||Vascular dementia:2||Particulate matter:2||Alzheimer disease:2||Physical activity:2||Pneumonia:2||Cholangiocarcinoma:2||Postural balance:2||Cholecystectomy:2||primary liver cancer:2||Prognostic factors:2||Hearing loss:2||public health:2||Metabolic syndrome:2||hepatitis B virusassociated intrahepatic cholangiocarcinoma:2||biliary malignancy:2||Rheumatoid arthritis:2||Exercise:2||selfdiagnosis:2||Intrahepatic cholangiocarcinoma:2||intrahepatic cholangiocarcinoma:2||SARSCoV2 infection:2||liver cancer:2||survival outcomes:2||MTORC2:1||Major depressive disorder:1||Mental health:1||Metaanalysis:1||Metabolic alcoholassociated liver disease:1||Metabolic dysfunction:1||Metabolic profiles:1||Moderatetovigorous physical activity:1||Mutational Landscape:1||Nervous system:1||Nested CaseControl Study:1||Neural regulation:1||Neurotransmitters:1||Nonalcoholic:1||Nrf2:1||OCT4:1||Older adults:1||Oneleg standing:1||Osteopontin:1||Osteoporotic fracture:1||Overall survival:1||Pain:1||Parkinson's disease risk:1||Pediatric liver transplantation:1||Pharmacoepidemiology:1||Posttransplant lymphoproliferative disorder:1||Postoperative depression:1||Primary liver cancer:1||RA:1||Recurrencefree survival:1||Republic of Korea:1||Respiratory Tract Infections:1||Rictor:1||Risk factor:1||Risk stratification:1||SARSCoV2 variants:1||Severe acute respiratory syndrome coronavirus 2:1||Sorafenib Resistance:1||South Korea:1||Staging system:1||Standards:1||Suicide risk:1||Surgical resection:1||Systolic pressure:1||TNFalpha:1||TP53:1||Targeted synthetic diseasemodifying antirheumatic drugs:1||Tramadol:1||Triglyceride:1||Tumorassociated lymphangiogenesis:1||VEGFR3 expression:1||Walking:1||Weight control:1||Young adults:1||acute liver injury:1||aging:1||alphaSMA:1||analytic (risk factors):1||arterial enhancement phase:1||artificial intelligence:1||asthma:1||asthma epidemiology:1||asthma pharmacology:1||big data:1||bile duct cancer:1||bile leak:1||biliary complications:1||biliary stricture:1||biomarker:1||body composition data:1||braingut axis (BGA):1||cancerassociated fibroblasts:1||cancerassociated lymphangiogenesis:1||cerebrovascular disease:1||cholangiocarcinoma:1||chronic kidney disease (CKD):1||chronic liver disease:1||chronic liver diseases:1||chronic obstructive pulmonary disease:1||cirrhosis:1||clinical interpretable model:1||cohort studies:1||communitylevel social trust:1||computed tomography:1||coronary heart disease:1||criteria:1||cytoprotective genes:1||deceased donor liver transplantation:1||defined daily dose:1||depressive disorder:1||diagnosis and prognosis:1||diagnostic test:1||distal cholangiocarcinoma (dCCA):1||double positive T cells:1||drug discovery:1||drugs:1||dual use:1||ducttoduct anastomosis:1||dyslipidemia:1||eGFR:1||early intervention:1||electronic inhalable products:1||embolism:1||entecavir:1||fibrosis:1||gut dysbiosis:1||hazard and risk:1||hearing loss:1||hepatectomy:1||hepatic resection:1||hepatocellular carcinoma prophylaxis:1||immune system:1||immunity:1||inflammation:1||insulin resistance:1||intrahepatic cholangiocarcinoma (iCCA):1||ischemic heart disease:1||isolation:1||lifestyle behavior:1||liver cirrhosis:1||liver injury:1||lncRNA:1||lobar PVTT:1||longterm sequelae:1||lymphangiogenesis:1||mass cytometry:1||mass screening:1||mesenchymaltolymphatic endothelial transition:1||metabolic dysfunctionassociated fatty liver disease:1||metabolic dysfunctionassociated steatotic liver disease:1||metabolic risk factors:1||metabolic syndrome prediction:1||miRNA:1||microvascular invasion:1||modifiable risk factor:1||noninvasive diagnosis:1||nonalcoholic fatty liver disease:1||noninvasive data:1||obesity:1||oneleg standing:1||organoid models:1||oxidative stress:1||particulate matter:1||perihilar cholangiocarcinoma (hiCCA):1||pharmacoepidemiology:1||physical activity:1||portal vein tumor thrombus:1||postacute COVID19 syndrome:1||preexisting depression:1||preclinical research:1||prediction:1||prediction model:1||predictive systems:1||prognostic factor:1||prognostic model:1||prostate cancer:1||proton pump inhibitor:1||public mental health:1||pulmonary metastasis:1||regression model:1||resection:1||risk factors:1||score system:1||scoring systems:1||segmental PVTT:1||severe COVID19:1||singlecell sequencing:1||smoking:1||social science:1||stroke:1||surgery:1||surgical resection:1||tenofovir:1||thrombosis:1||thyroid cancer:1||transarterial chemoembolization:1||transplantation:1||treatments:1||tumor microenvironment:1||tumorassociated lymphangiogenesis:1||type 2 diabetes mellitus:1||vascular complications:1||viral hepatitis:1||Aged:1||weight change:1||Aging:1||Air pollutants:1||Alcohol:1||Alcohol consumption:1||Allergic disease:1||Allergic rhinitis:1||Alzheimer's disease:1||Alzheimer’s disease:1||Angiotensin converting enzyme inhibitors:1||Angiotensin receptor blockers:1||Antibioticsinduced depression:1||Antihypertensive drugs:1||Asthma:1||Atopic dermatitis:1||Autophagy:1||Bell's palsy:1||Bile duct cancer:1||Biologic diseasemodifying antirheumatic:1||Biologic diseasemodifying antirheumatic drugs:1||Blood pressure:1||Body Weight:1||Body composition:1||Bodymass index, BMI:1||Braingut axis:1||Breast cancer survivor:1||Cancer:1||Cancer survivors:1||Cardiovascular risk factors:1||Cholesterol:1||Clinicopathological characteristics:1||Cohort:1||Cohort Study:1||Cohort studies:1||Colorectal cancer:1||Diabetes Mellitus:1||Diastolic pressure:1||Drug survival:1||EpsteinBarr virus:1||Gut microbiota:1||HDL:1||Hemorrhage stroke:1||Hepatic ischemia/reperfusion injury:1||Hepatic resection:1||Hepatic steatosis:1||Hepatic steatosis index:1||Hepatitis B virus:1||Hepatitis B virusassociated intrahepatic cholangiocarcinoma:1||Hepatocellular Carcinoma:1||Hepatocellular carcinoma (HCC):1||Herpes zoster:1||HydroxymethylglutarylCoA reductase inhibitors:1||Infection:1||Interleukin 26:1||Inverse probability of treatment weighting:1||Ischemic stroke:1||Leukemia:1||Liver cancer:1||Liver diseases:1||Liver transplantation:1||Living donor liver transplantation:1||Locoregional therapy:1||Lung cancer:1||Lymphoma:1||

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE